Dizal Pharmaceuticals
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS15
PHASE 3 / 2-34
RECRUITING11
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO18%
Delay Index: of 11 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Dizal Pharmaceuticals on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Sunvozertinib NCT05712902 |
P2 | Active, not recruiting | Non-Small Cell Lung Cancer | 104 | 2022-10-17 |
| Sunvozertinib NCT03974022 |
P1/2 | Active, not recruiting | Non-Small Cell Lung Cancer | 315 | 2024-07-29 (+20 mo) |
| DZD9008 plus Bevacizumab NCT06276283 |
P2 | Recruiting | Non-small Cell Lung Cancer | 60 | 2025-12-31 (+7 mo) |
| sunvozertinib NCT05668988 |
P3 | Active, not recruiting | Non-small Cell Lung Cancer | 324 | 2026-01-16 (-1 mo) |
| DZD6008 NCT07070440 |
P1/2 | Recruiting | Non Small Cell Lung Cancer | 180 | 2027-06 |
| DZD8586 dose level 1 NCT07294365 |
P2 | Recruiting | Immune Thrombocytopenia (ITP) | 60 | 2027-07 |
| DZD8586 NCT06539182 |
P2 | Recruiting | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 155 | 2027-09 |
| Golidocitinib NCT07234162 |
P3 | Recruiting | Peripheral T-cell Lymphoma | 218 | 2027-11-30 |
| DZD6008 NCT07079475 |
P1/2 | Recruiting | Non-Small Cell Lung Cancer | 220 | 2028-06 (-6 mo) |
| GW5282 NCT07328217 |
P1/2 | Recruiting | Advanced Solid Tumors | 203 | 2028-12 |
| DZD8586 NCT07139873 |
P3 | Recruiting | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 250 | 2029-01 |
| GW5282 combined with Golidocitinib NCT07496229 |
P1/2 | Recruiting | T-cell Lymphomas | 220 | 2029-09 |
| DZD8586 NCT07154264 |
P2 | Recruiting | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 66 | 2029-12 |
| DZD8586+R-CHOP NCT07059650 |
P1/2 | Recruiting | Diffuse Large B-Cell Lymphoma | 150 | 2030-10 |
| Birelentinib NCT07712588 |
P2/3 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 880 | 2031-01 |